ClinicalTrials.gg
CompletedNCT05444413Updated Sep 8, 2022

Platelet-rich Plasma in the Treatment of Intractable Postherpetic Neuralgia

A Phase 1 interventional study of ultrasound-guided platelet rich plasma nerve block in PHN - Post-Herpetic Neuritis, sponsored by Affiliated Hospital of Nantong University. Completed at 1 site in China. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-08.

Sponsored by Affiliated Hospital of Nantong University · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2022, registered Jun 2022).
Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
40 Years to 70 Years
Sex
All
01

Study summary

used ultrasound-guided platelet rich plasma nerve block to treat Intractable Postherpetic Neuralgia.

Read the detailed description

Postherpetic neuralgia (PHN) is a kind of pain caused by varicella zoster virus invading the human body and infecting the corresponding ganglia. The affected ganglia are inflamed or even necrotic, affecting the nerve endings, the dorsal horn of the spinal cord and the sensory nerve tissues below, and the course of the disease is more than one month or more. Most patients can avoid PHN by timely and effective treatment in the acute herpes zoster period. However, some patients with intractable postherpetic neuralgia fail to receive timely and effective pain control treatment in the early stage of the disease, and the current commonly used clinical treatment methods often fail to achieve effective treatment results. Such patients often have a long course of disease, which can last for three to five years or even longer, Nerve damage is also more serious. Long term pain has seriously affected the quality of life of such patients. Therefore, how to quickly and effectively control pain has become the diagnosis and treatment goal of such patients with intractable post herpetic neuralgia. Platelet rich plasma (PRP) was widely used in muscle and bone repair due to its function of promoting tissue repair in the early stage. Recently, it was found that PrP can also promote nerve repair. Therefore, in order to further explore the therapeutic effect of PRP on refractory PHN patients, our department used ultrasound-guided platelet rich plasma nerve block to treat Intractable PHN.

02

Conditions studied

  • PHN - Post-Herpetic Neuritis

Browse trials for

Keywords

  • platelet-rich plasma
  • Intractable postherpetic neuralgia
03

In context

Neuritis

73 studies on the registry are indexed under Neuritis; 20 are open to participants now.

This study's enrollment of 32 is below the median of 48 across 51 interventional studies indexed under Neuritis.

Browse Neuritis studies →

Lead sponsor

Affiliated Hospital of Nantong University is the lead sponsor of 97 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria of PHN: have a history of acute herpes zoster, the pain lasts for more than half a year, and there is paroxysmal pain in the affected nerve distribution area;
  • Preoperative visual analog scale (VAS) score ≥ 5;
  • Those who can cooperate with the treatment;
  • We agreed to inject rich plasma into nerve block under the guidance of ultrasound, and signed the form.

Exclusion criteria

Exclusion Criteria:

  • Systemic infection or puncture local infection;
  • Serious disturbance of cardiovascular and cerebrovascular function;
  • Abnormal bleeding and coagulation function or complicated with blood system diseases;
  • Mental disorders;
  • Severe dysfunction of important organs in the body
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    ultrasound-guided platelet rich plasma nerve block combined with drugs

    selected patients were treated by the ultrasound-guided platelet rich plasma nerve block once a week for the 4 consecutive weeks while they were given the regular medicine which are taking pregabalin and amitriptyline hydrochloride orally, and the dosage shall be increased or decreased according to the patient's condition.

    Biological: ultrasound-guided platelet rich plasma nerve block

Interventions

  • Biologicalultrasound-guided platelet rich plasma nerve block

    selected persons are treated by ultrasound-guided platelet rich plasma nerve block and the regular medicine

06

What researchers measure

Primary outcomes

  1. The changes from degree of pain that patients feel after the treatment are assessed by the numerical rating scale (NRS).

    This method is composed of 11 numbers from 0 to 10. Patients use 11 numbers from 0 to 10 to describe the intensity of pain. (0="no pain"and 10=the "worst pain")

    Time frame: Change from the numerical rating scale at 6 months

Secondary outcomes

  1. The changes from degree of pain that patients feel after the treatment are also assessed by the Short-form McGill Pain Questionnaire(SF-MPQ).

    When evaluating item (1), ask the thinker questions one by one, and mark the corresponding level according to the pain level the thinker answers. When evaluating item (2), vas ruler shall be adopted. This ruler is a 10cm long swimming ruler with 10 graduations marked on one side and "0" and "10" at both ends, indicating no pain,"10" represents the most severe pain that the patient can't bear in his life. During clinical use, the side with scale is turned away from the patient, and the patient is asked to mark the corresponding position representing his pain level in the past day on the ruler. The evaluator evaluates the number of patients according to the position marked by the patient (for example, 5.4cm is 5.4 points), and records it in the table. When evaluating item (3), mark the corresponding score according to the patient's subjective feelings. Finally, the total scores of PRI, vas and PPI were evaluated. (The higher the total score, the more severe the pain)

    Time frame: Change from the total score of Short-form McGill Pain Questionnaire at 6 months

  2. The changes from degree of the patient' sleep quality after the treatment are assessed by the Athens Insomnia Scale.

    Ask the examinee to carefully review his sleep experience in the past one month for questions ① - ⑧. If it happens to you at least three times a week, circle the corresponding self-assessment results. Then calculate the total score for evaluation. Assessment result judgment: (1) If the total score is less than 4, there is no sleep disorder: (2) if the total score is 4-6, it is suspected that there is a big sleep; (3) If the total score is above 6: Insomnia

    Time frame: Change from the patient' sleep quality at 6 months

07

Study locations

1 site
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu 226000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05444413
Lead sponsor
Affiliated Hospital of Nantong University
Responsible party
Yuan Zhou (Deputy chief physician, Affiliated Hospital of Nantong University) — Principal investigator
First posted
Jul 5, 2022
Start date
Mar 3, 2022
Primary completion
May 3, 2022
Completion
Jul 1, 2022
Last update
Sep 8, 2022

Study contacts

yuan zhou, doctor
study director · Affiliated Hospital of Nantong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion